The Latest Cardiac and Vascular News
Aligned with CHOP and AHA’s shared mission to improve cardiac care, grant supports research aiming to discover new hormones secreted from the heart PHILADELPHIA, Aug. 4, 2022 /PRNewswire/ — Children’s Hospital of Philadelphia (CHOP) has received a $400,000 grant from the American Heart Association (AHA) to help study heart-secreted hormones. The funding, which will be disbursed in yearly increments […]
LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it has signed a collaboration agreement with the German Heart Centre Berlin (DHZB), a leading medical research institute specializing in cardiovascular disease. This agreement focuses on the development of a suite of innovative solutions that will facilitate the diagnosis and treatment […]
– Patisiran Met the Primary Endpoint with a Statistically Significant Improvement in 6-Minute Walk Test Compared to Placebo at 12 Months – – Patisiran Also Met the First Secondary Endpoint with a Statistically Significant Improvement in Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire, Compared to Placebo […]
NORRISTOWN, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc., announced today successful 30-day outcomes in the first two patients receiving the Optimum Transcatheter Aortic Valve (Optimum TAV™). The implantations were performed by the Principal Investigator, Jaroslaw Trebacz, MD, at the Specialty Hospital Jana Pawla II, Krakow, Poland. The study was approved by the […]
Company to Distribute Recent FDA-Approved Treatment for Reducing Bad Cholesterol CORRECTION…by Soleo Health August 01, 2022 07:17 PM Eastern Daylight Time FRISCO, Texas–(BUSINESS WIRE)–Headline of release dated July 26, 2022, should read: Soleo Health Selected as Limited Drug Distribution Partner for Administration of LEQVIO® The updated release reads: SOLEO HEALTH […]
SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP® Cell Therapy Heart Failure Trial. “The Ottawa Heart […]
Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso® per session Achieved therapeutic levels by Month 2 and continued to titrate to higher levels for approximately one year on average before rolling into extension trial Safety […]
By combining AI-guided echocardiograms and Virtual-First cardiology care, the new partnership enables early disease identification and management for patients from the comfort of their homes BRISBANE, Calif. and NEW YORK, July 28, 2022 /PRNewswire/ — Caption Health, the leader in providing services and AI to improve heart ultrasound access, and Heartbeat Health, the nation’s largest Virtual […]
Phase 2b RE-THINC ESRD study of fesomersen met its primary endpoint in patients with end-stage renal disease on hemodialysis Fesomersen demonstrated substantial and statistically significant reductions in Factor XI activity levels Fesomersen, a novel Factor XI antisense inhibitor designed to prevent thrombosis, was safe and well-tolerated in the study with up to […]
More Effective SofPulse® Results Compared With Bioelectronics RecoveryRx® Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and […]
